Metastatic Uveal Melanoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: closed (31 August 2021) | Viewed by 31019
Special Issue Editor
Special Issue Information
Dear Colleagues,
Uveal melanoma (UM) is the most common intraocular malignant tumor in adults. Primary UMs are effectively treated by plaque radiotherapy or enucleation; however, 30–50% of UM patients ultimately succumb to systemic recurrence, especially liver metastasis.
Two major mutations are present in the majority of metastatic UMs: (1) activating mutations in the alpha subunits of heterotrimeric G proteins (GNAQ or GNA11) and related genes (PLCB4, CYSLTR2) and (2) mutations affecting deubiquitinating enzymes (BAP1) or RNA splicing factors (SF3B1). Various inhibitors have been tested in attempts to block signals from mutant GNAQ/GNA11 to downstream pathways, including the MEK-ERK1/2 and AKT-PI3K pathways, with marginal clinical benefit. Furthermore, the microenvironment of metastatic UM in the liver is detrimental to antitumor immune responses and contributes to poor responses to immune checkpoint blockades.
This Special Issue will highlight the biological characteristics of metastatic UM and its microenvironment, covering both basic and clinical aspects to develop a strategy to improve the outcome of metastatic UM patients.
Prof. Takami Sato
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- uveal melanoma
- metastasis
- liver
- tumor microenvironment
- tumor–microenvironment interaction
- dormancy
- research model
- signal inhibitor
- immunotherapy